CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CRMD CorMedix Inc.

Pre-Mkt 09-18 05:11:21 EDT

7.79

-0.03

-0.38%

盘前7.70

-0.09-1.16%

04:23 EDT

High7.92	Low7.70	Vol684.75K
Open7.86	D1 Closing7.82	Amplitude2.88%
Mkt Cap607.19M	Tradable Cap514.33M	Total Shares77.94M
T/O5.32M	T/O Rate1.04%	Tradable Shares66.02M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CRMD","market":"US","secType":"STK","nameCN":"CorMedix Inc.","latestPrice":7.79,"timestamp":1789675200000,"preClose":7.82,"halted":0,"volume":684745,"hourTrading":{"tag":"盘前","latestPrice":7.7,"preClose":7.79,"latestTime":"04:23 EDT","volume":84,"amount":646.8000000000001,"timestamp":1789719817545,"change":-0.09,"changeRate":-0.011553,"amplitude":0},"delay":0,"changeRate":-0.003836317135549904,"floatShares":66024300,"shares":77944324,"eps":2.083064,"marketStatus":"Pre-Mkt","change":-0.03,"latestTime":"09-18 05:11:21 EDT","open":7.86,"high":7.92,"low":7.695,"amount":5315808.27553,"amplitude":0.028772,"askPrice":8.87,"askSize":100,"bidPrice":7.1,"bidSize":100,"shortable":3,"etf":0,"ttmEps":2.083064,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789738200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1273723200000,"exchange":"NASDAQ","adjPreClose":7.79,"preHourTrading":{"tag":"盘前","latestPrice":7.7,"preClose":7.79,"latestTime":"04:23 EDT","volume":84,"amount":646.8000000000001,"timestamp":1789719817545,"change":-0.09,"changeRate":-0.011553,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":7.79,"preClose":7.79,"latestTime":"19:30 EDT","volume":31867,"amount":248292.321,"timestamp":1789687803683,"change":0,"changeRate":0,"amplitude":0.002567},"volumeRatio":0.8598128754195394,"impliedVol":0.4398,"impliedVolPercentile":0.08},"requestUrl":"/m/hq/s/CRMD","defaultTab":"news","newsList":[{"id":"2659128386","title":"CorMedix's New Major DefenCath Customer Backs 2026 Volumes, Durability Through 2027, RBC Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2659128386","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659128386?lang=en_us&edition=fundamental","pubTime":"2026-08-14 23:30","pubTimestamp":1786721454,"startTime":"0","endTime":"0","summary":"CorMedix's  last major customer for its DefenCath solution could buoy 2026 volumes and back franchise durability in 2027 and beyond, RBC Capital Markets said in a Thursday note.DefenCath is intended to prevent catheter-related bloodstream infections in patients with end-stage renal disease and the last multi-year contract win with a large dialysis organization in the US indicates continued demand and should boost H2 order volume, RBC said, noting the drug's potential to top $199 million in 2026 revenue.RBC also noted the company's upcoming supplemental new drug application for Rezzayo, which is currently a treatment of candidemia and invasive candidiasis, as a potential growth driver in 2027. Rezzayo's potential label expansion in prophylaxis could unlock a $200 million market opportunity for CorMedix, the brokerage added.RBC raised its price target on CorMedix to $14 from $13, with an outperform rating.Price: 7.75, Change: -0.39, Percent Change: -4.77","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659966149","title":"Annovis Bio Q2 Loss Widens as R&D Costs Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2659966149","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659966149?lang=en_us&edition=fundamental","pubTime":"2026-08-14 20:15","pubTimestamp":1786709731,"startTime":"0","endTime":"0","summary":"Annovis Bio Q2 loss widens as R&D costs riseOverviewUS biotech firm's Q2 net loss per share widened yr/yrCompany fully enrolled pivotal Phase 3 Alzheimer's trial, exceeding original targetQ2 research ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260814:nL1N44B0EG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PMN","BK4007","BK4139","ANVS","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659146854","title":"RBC Adjusts Price Target on CorMedix to $14 From $13, Maintains Outperform Speculative Risk Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2659146854","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659146854?lang=en_us&edition=fundamental","pubTime":"2026-08-14 19:36","pubTimestamp":1786707415,"startTime":"0","endTime":"0","summary":"CorMedix (CRMD) has an average rating of buy and mean price target of $15.40, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659161058","title":"CorMedix Shares Rise After Q2 Results, Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2659161058","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659161058?lang=en_us&edition=fundamental","pubTime":"2026-08-14 02:41","pubTimestamp":1786646484,"startTime":"0","endTime":"0","summary":"CorMedix  shares were up over 11% in Thursday trading following its Q2 results and guidance.Earlier, the company reported a Q2 earnings of $0.29 per diluted share, up from $0.28 a year earlier.Revenue for the three months ended June 30 was $101.9 million, up from $39.7 million a year earlier.Analysts polled by FactSet expected $97.4 million.For 2026, the company kept its revenue guidance of $325 million to $345 million, while raising its adjusted EBITDA guidance to a range of $125 million to $140 million.Analysts expected $335.3 million for revenue.Price: 7.95, Change: +0.85, Percent Change: +11.90","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659169742","title":"Analysts Are Bullish on Top Healthcare Stocks: Parabilis Medicines, Inc. (PBLS), Cormedix (CRMD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2659169742","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659169742?lang=en_us&edition=fundamental","pubTime":"2026-08-14 01:30","pubTimestamp":1786642207,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Parabilis Medicines, Inc. (PBLS) and Cormedix (CRMD)...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-parabilis-medicines-inc-pbls-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-parabilis-medicines-inc-pbls-cormedix-crmd-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659119166","title":"U.S. Stocks on the MOVE-EnerSys, Netflix, Salesforce","url":"https://stock-news.laohu8.com/highlight/detail?id=2659119166","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659119166?lang=en_us&edition=fundamental","pubTime":"2026-08-14 00:18","pubTimestamp":1786637899,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-EnerSys, Netflix, SalesforceAugust 13 (Reuters)-The S&P 500 hit an intraday record high on Thursday, boosted by technology stocks, as a drop in crude prices lifted risk ap","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL6N44A14N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBM","NFLX","STUB","SPCE","CBRS","LWAY","LUNR","OPEN","WQTM","LESL","CGEM","HLIT","PYXS","MSGS","AKAM","CSCL","BIRK","NEM","ABEO","TRUM","STAA","DELL","CRMD","RKLX","LNSR","DIOD","OMER","CSCS","FIVE","CRM","DKL","WSPC","AVAH","MH","ENS","OTLK","CSCO","TPR","LUNL","AGMI","HPQ","ARX","XLC","DERM","RKLB","DIPR","ABCL","GLNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659632421","title":"CorMedix Stock Jumps on Strong DefenCath Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2659632421","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659632421?lang=en_us&edition=fundamental","pubTime":"2026-08-13 22:56","pubTimestamp":1786632982,"startTime":"0","endTime":"0","summary":"CorMedix Q2 earnings beat estimates as sales more than doubled, DefenCath revenue grew, and the company reaffirmed 2026 sales guidance.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/earnings/26/08/61179766/cormedix-stock-jumps-on-strong-defencath-sales","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SMA","BK4007","CRMD","BK4217"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659150530","title":"CorMedix Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2659150530","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659150530?lang=en_us&edition=fundamental","pubTime":"2026-08-13 21:31","pubTimestamp":1786627874,"startTime":"0","endTime":"0","summary":"CorMedix Inc. reports results for the quarter ended June 30 - Earnings SummaryCorMedix Inc.CRMD.OQreported quarterly adjusted earnings of 32 cents per share for the quarter ended June 30, higher than ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL8N44A1AY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659515681","title":"CorMedix Shares Rise 7.1% Premarket After Q2 Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2659515681","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659515681?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:46","pubTimestamp":1786621615,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nFWN44A0J4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659151875","title":"CorMedix Beats Q2 Revenue Estimates on DefenCath Growth, Raises FY Adjusted Ebitda Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2659151875","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659151875?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:42","pubTimestamp":1786621337,"startTime":"0","endTime":"0","summary":"CorMedix beatsQ2 revenue estimates on DefenCath growth, raises FY adjusted EBITDA guidanceOverviewUS biopharma firm's Q2 revenue rose, beating analyst expectationsEPS for Q2 beat analyst expectationsC","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nL1N44A0I7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","CANC","MEDI","OMER","BK4139","BK4505","MEMS","BK4585","CRMD","LEGN","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159753","title":"Cormedix Q2 EPS $0.29 Beats $0.25 Estimate, Sales $101.931M Beat $95.621M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159753","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159753?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:34","pubTimestamp":1786620863,"startTime":"0","endTime":"0","summary":"Cormedix Q2 EPS $0.29 Beats $0.25 Estimate, Sales $101.931M Beat $95.621M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/CRMD","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659251159","title":"CorMedix Q2 2026 Net Income Rises 31.1% to $26 Million; Revenue More than Doubled to $101.9 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659251159","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659251159?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:33","pubTimestamp":1786620791,"startTime":"0","endTime":"0","summary":"CorMedix Q2 2026 net income rises 31.1% to $26 million; revenue more than doubled to $101.9 millionCorMedix posted Q2 2026 consolidated revenue of USD 101.9 million, up 156.57% from a year earlier.Net","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nNDLb3780v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","LU2210149790.SGD","IE00BN0W2T93.GBP","CRMD","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210150020.SGD","BK4112","LU2095319765.USD","BK4588","IE00BN0W2V16.EUR","BCDF","IE00B3QW5Z07.USD","LU0314104364.USD","SG9999014013.SGD","IE00BGHQF748.EUR","BK4007","BK4585","SG9999014021.USD","IE00BN0W2W23.USD","NDAQ","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659519821","title":"CorMedix Q2 Cash & Investments USD 256.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2659519821","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659519821?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX749V52:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659159449","title":"CorMedix - Maintains FY 2026 Revenue Guidance $325-$345 Mln; Raises FY Adj Ebitda Guidance to $125-$140 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2659159449","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659159449?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX749V52:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659015997","title":"CorMedix Q2 Basic EPS USD 0.33","url":"https://stock-news.laohu8.com/highlight/detail?id=2659015997","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659015997?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nPLX749V52:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659191159","title":"CorMedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2659191159","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659191159?lang=en_us&edition=fundamental","pubTime":"2026-08-13 19:30","pubTimestamp":1786620601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260813:nTUA8PH1XD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659158478","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2659158478","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2659158478?lang=en_us&edition=fundamental","pubTime":"2026-08-13 18:00","pubTimestamp":1786615200,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.Company                                   Symbol     Quarter  Mean  Report Time. ·ADC Ther. Ltd                                   2Q      (.22)   7:30 AM. ·Applied Ind Tech                                 4Q      2.92    6:30 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLTE","BEAT","CLBT","DEFT","AIRO","AIT","ADCT","BSP","CAAP","FBRX","AMAT","DRUG","ACXP","CLRB","ASND","BRUN","AVAH","AIRJ","ARX","ESEA","BAK","BZAI","EU","CAMP","CAPR","BAP","VIPS","BTBT","EVTL","CAN","BIRK","AEYE","STNE","CRDL","AVR","DDS","BN","AEBI","ETON","DCGO","ACOG","DARE","ELMT","ALH","DLO","ABEO","ARCO","CELC","CRMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626623","title":"CorMedix Faces Sept. 23 Hearing on Settlement of Shareholder Derivative Lawsuits","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626623","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626623?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134055,"startTime":"0","endTime":"0","summary":"CorMedix faces Sept. 23 hearing on settlement of shareholder derivative lawsuitsCorMedix faces proposed settlements to end two shareholder derivative suits tied to alleged disclosure failures on Defen","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nNDL5lgT48:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657626612","title":"CorMedix - on July 24, Court Granted Preliminary Approval of CorMedix Derivative Lawsuit Settlement - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2657626612","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657626612?lang=en_us&edition=fundamental","pubTime":"2026-08-08 04:20","pubTimestamp":1786134006,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260807:nFWN44417H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRMD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655898342","title":"CorMedix to Report Q2 Results, Host Corporate Update Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2655898342","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655898342?lang=en_us&edition=fundamental","pubTime":"2026-07-29 20:33","pubTimestamp":1785328381,"startTime":"0","endTime":"0","summary":"CorMedix to report Q2 results, host corporate update callCorMedix will report second-quarter 2026 results before the market opens on Aug. 13, 2026.A corporate update conference call is scheduled for A","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDLxZq6S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","SG9999014013.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","NDAQ","SG9999014005.SGD","SG9999014021.USD","IE00B64PRP62.GBP","LU2095319765.USD","BK4112","BK4588","IE00BN0W2V16.EUR","BCDF","BK4007","IE00BGHQF748.EUR","SG9999014039.USD","IE00BKPKM429.USD","IE00BN0W2T93.GBP","CRMD","BK4585","LU2210150020.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cormedix.com","stockEarnings":[{"period":"1week","weight":-0.0214},{"period":"1month","weight":-0.0465},{"period":"3month","weight":-0.1015},{"period":"6month","weight":0.2464},{"period":"1year","weight":-0.2995},{"period":"ytd","weight":-0.3302}],"compareEarnings":[{"period":"1week","weight":0.0063},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0212},{"period":"6month","weight":0.1758},{"period":"1year","weight":0.1569},{"period":"ytd","weight":0.1183}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.133293},{"month":2,"riseRate":0.5,"avgChangeRate":0.066552},{"month":3,"riseRate":0.5,"avgChangeRate":0.041342},{"month":4,"riseRate":0.5,"avgChangeRate":-0.005656},{"month":5,"riseRate":0.25,"avgChangeRate":-0.108379},{"month":6,"riseRate":0.529412,"avgChangeRate":0.045878},{"month":7,"riseRate":0.411765,"avgChangeRate":0.049729},{"month":8,"riseRate":0.588235,"avgChangeRate":0.029573},{"month":9,"riseRate":0.352941,"avgChangeRate":0.022418},{"month":10,"riseRate":0.4375,"avgChangeRate":0.043001},{"month":11,"riseRate":0.4375,"avgChangeRate":0.046811},{"month":12,"riseRate":0.4375,"avgChangeRate":0.057824}],"exchange":"NASDAQ","name":"CorMedix Inc.","nameEN":"CorMedix Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.50.0","shortVersion":"4.50.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CorMedix Inc.,CRMD,CorMedix Inc.股票,CorMedix Inc.股票老虎,CorMedix Inc.股票老虎国际,CorMedix Inc.行情,CorMedix Inc.股票行情,CorMedix Inc.股价,CorMedix Inc.股市,CorMedix Inc.股票价格,CorMedix Inc.股票交易,CorMedix Inc.股票购买,CorMedix Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CorMedix Inc.(CRMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CorMedix Inc.(CRMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}